Skip to main content
Premium Trial:

Request an Annual Quote

Cartagenia, Interactive Biosoftware Enter Software Integration Agreement

Premium

Cartagenia and Interactive Biosoftware have signed an agreement allowing Cartagenia to integrate IB's Alamut gene visualization software into its BenchLab, a web-based software tool for interpreting genomic variation in routine diagnostics.

The combined solution will merge BenchLab’s variant data filtering, interpretation, and management capabilities with Alamut’s annotation and visualization functionalities. It will let users assess candidate variants in context of phenotype as well as integrate their findings and conclusions with a lab or hospital’s laboratory information management system or electronic health record system.

Under the terms of the agreement, Cartagenia and IB will each market the combined solution to their respective customers, while continuing to sell their own products independently.

Andre Blavier, IB’s CEO, described the alliance between the two companies as a natural fit.

With the integration deal, “our Alamut solution is now extended with capabilities which were previously unavailable to us, such as patient database management, massively parallel variant filtering, and advanced lab reporting," Blavier said.

Furthermore, many BenchLab customers already use IB’s Alamut, Herman Verrelst, Cartagenia’s CEO, noted.

“The high level of automation and the lab-validated variant filtration pipelines in BenchLab are perfectly complemented by the Alamut gene browser that allows lab technicians to visualize specific variants of interest,” he said in a statement. “A technical integration of the two systems provides a single workflow experience.”

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.